Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Synthesis
|
November 6, 2018
Tartaric Acid and Tartrates in the Synthesis of Bioactive Molecules
Arun K Ghosh, Elena S Koltun, Geoffrey Bilcer
Journal of the American Chemical Society
|
February 14, 2002
Ring scission of diastereomeric 4-butylspiropentylcarbinyl radicals as a chemical model for identifying enzyme-catalyzed FAD adducts resulting from spiropentylacetyl-CoA
Lev Lis, Elena S Koltun, Hung-wen Liu, et al.
Cancer Research
|
May 1, 2020
Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment
Elsa Quintana, Christopher J Schulze, Darienne R Myers, et al.
Journal of Medicinal Chemistry
|
March 8, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
James Cregg, Anne V Edwards, Stephanie Chang, et al.
Nature Cell Biology
|
August 15, 2018
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
Robert J Nichols, Franziska Haderk, Carlos Stahlhut, et al.
Cancer Discovery
|
June 22, 2026
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Kyle J Seamon, Yongxian Zhuang, Yu Chi Yang, et al.
Journal of Medicinal Chemistry
|
April 14, 2012
Discovery and characterization of an inhibitor of glucosylceramide synthase
Steven Richards, Christopher J Larson, Elena S Koltun, et al.
Journal of Medicinal Chemistry
|
February 24, 2025
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
James Cregg, Kristof Pota, Aidan C A Tomlinson, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)
Kenneth D Rice, Naing Aay, Neel K Anand, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 1, 2012
The design, synthesis, and biological evaluation of PIM kinase inhibitors
Amy Lew Tsuhako, David S Brown, Elena S Koltun, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Synthesis
|
November 6, 2018
Tartaric Acid and Tartrates in the Synthesis of Bioactive Molecules
Arun K Ghosh, Elena S Koltun, Geoffrey Bilcer
Journal of the American Chemical Society
|
February 14, 2002
Ring scission of diastereomeric 4-butylspiropentylcarbinyl radicals as a chemical model for identifying enzyme-catalyzed FAD adducts resulting from spiropentylacetyl-CoA
Lev Lis, Elena S Koltun, Hung-wen Liu, et al.
Cancer Research
|
May 1, 2020
Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment
Elsa Quintana, Christopher J Schulze, Darienne R Myers, et al.
Journal of Medicinal Chemistry
|
March 8, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
James Cregg, Anne V Edwards, Stephanie Chang, et al.
Nature Cell Biology
|
August 15, 2018
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
Robert J Nichols, Franziska Haderk, Carlos Stahlhut, et al.
Cancer Discovery
|
June 22, 2026
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers
Kyle J Seamon, Yongxian Zhuang, Yu Chi Yang, et al.
Journal of Medicinal Chemistry
|
April 14, 2012
Discovery and characterization of an inhibitor of glucosylceramide synthase
Steven Richards, Christopher J Larson, Elena S Koltun, et al.
Journal of Medicinal Chemistry
|
February 24, 2025
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
James Cregg, Kristof Pota, Aidan C A Tomlinson, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)
Kenneth D Rice, Naing Aay, Neel K Anand, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 1, 2012
The design, synthesis, and biological evaluation of PIM kinase inhibitors
Amy Lew Tsuhako, David S Brown, Elena S Koltun, et al.
Page
of 2